MedTrace Logo

4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

NCT02115204 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2011

Last updated 2019-10-03

No results posted yet for this study

Summary

Taxane-based adjuvant chemotherapy is standard in node-positive (N+) early breast cancer (BC). The magnitude of benefit in intermediate-risk N+ early BC is still unclear. West German Study Group and "Arbeitsgemeinschaft Gynäkologische Onkologie" (WSG-AGO) EC-Doc is a large trial evaluating modern sequential taxane-based chemotherapy in the subgroup with 1-3 involved lymph nodes (LN).

Conditions

Interventions

DRUG

Epirubicin

DRUG

Cyclophosphamide

DRUG

Docetaxel

DRUG

Methotrexate

DRUG

5-fluorouracil

Sponsors & Collaborators

  • AGO Germany

    collaborator UNKNOWN

  • West German Study Group

    lead OTHER

Principal Investigators

  • Ulrike Nitz, Prof. Dr. · Ev. Hospital Bethesda, Moenchengladbach

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-06-30
Primary Completion
2005-08-31
Completion
2010-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02115204 on ClinicalTrials.gov